WAT

ACCE-researched
Waters Corporation Common Stock
Healthcare · Diagnostics & Research · NYSE · United States
$421.63-1.88%
Market cap $41.4BNext earnings 2026-11-03Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$421.63+0.0%
confidence-weighted across 3 of 6 models
Now $421.63
$421.63
$79.48$102.17
AvoidSilver65
Price vs fair value
369.6% above
-78.7% to fair value
ACCE score
61
out of 100
Analysts
32% buy
22 covering
P/E
106.5x
forward 25.5x
1-year return
+37.6%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 2 flags
  • high
    Extreme valuation multiples
    P/E of 44.2x and EV/EBITDA of 27.3x are exceptionally high, suggesting significant overvaluation risk.
  • moderate
    Low ROE performance
    ROE of only 5.2% is quite poor for a healthcare diagnostics company with such premium valuation.
Reports in 43 days, last quarter beat by 0.0%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+39.4% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bearish32% buy · 22 covering analysts
● Strong buy 6● Buy 1● Hold 15● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 0.0x106.5xhigh 106.5x
ROEbetter than 17% of peers
low -13%2%high 74%
Div yieldbetter than 67% of peers
low 0.0%0.0%high 0.9%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
IDXXIDEXX Laboratories Inc. Common Stock$40.3B36.074.2%0.530.0%-Compare
IQVIQVIA Holdings Inc. Common Stock$43.9B33.122.8%2.420.0%-Compare
AAgilent Technologies Inc. Common Stock$44.1B30.921.0%0.500.7%-Compare
LONN.SWLonza Group$46.2B35.212.9%0.460.9%-Compare
ILMNIllumina Inc. Common Stock$36.2B44.632.3%0.730.0%-Compare
NTRANatera Inc. Common Stock$53.2B--12.5%0.050.0%-Compare

Sector report card

Where WAT ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 43 days, last quarter beat by 0.0%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+3.3%
1 month
+1.4%
3 months
+18.6%
6 months
+41.0%
YTD
+11.0%
1 year
+37.6%

SEC filings

40 filings
August 2026
Aug 21
8-KCurrent reportPeriod 2026-08-17
Aug 11
10-QQuarterly reportPeriod 2026-07-04
Aug 7
Form 4Insider transactionPeriod 2026-08-06
37 more filings + AI summaries on Investor+.INVESTOR